191 related articles for article (PubMed ID: 28246006)
1. Efficacy of bevacizumab therapy in recurrent malignant gliomas in relation to the prior recurrence pattern or tumor location.
Matsuda M; Ishikawa E; Yamamoto T; Akutsu H; Takano S; Matsumura A
J Clin Neurosci; 2017 Jun; 40():115-119. PubMed ID: 28246006
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
3. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
Toh CH; Liau CT; Wei KC; Castillo M
J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
[TBL] [Abstract][Full Text] [Related]
4. Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab.
Thomas A; Rosenblum M; Karimi S; DeAngelis LM; Omuro A; Kaley TJ
CNS Oncol; 2018 Jan; 7(1):7-13. PubMed ID: 29388793
[TBL] [Abstract][Full Text] [Related]
5. A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma.
Pace A; Mandoj C; Antenucci A; Villani V; Sperduti I; Casini B; Carosi M; Fabi A; Vidiri A; Koudriavtseva T; Conti L
J Neurooncol; 2018 Jul; 138(3):527-535. PubMed ID: 29594657
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients.
Detti B; Scoccianti S; Teriaca MA; Maragna V; Lorenzetti V; Lucidi S; Bellini C; Greto D; Desideri I; Livi L
Radiol Med; 2021 Sep; 126(9):1249-1254. PubMed ID: 34081269
[TBL] [Abstract][Full Text] [Related]
7. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
Cha Y; Kim YJ; Lee SH; Kim TM; Choi SH; Kim DW; Park CK; Kim IH; Kim JH; Kim E; Choi B; Kim CY; Kim IA; Heo DS
Cancer Res Treat; 2017 Jan; 49(1):129-140. PubMed ID: 27188199
[TBL] [Abstract][Full Text] [Related]
8. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma.
Kurz SC; Cabrera LP; Hastie D; Huang R; Unadkat P; Rinne M; Nayak L; Lee EQ; Reardon DA; Wen PY
Neurology; 2018 Oct; 91(14):e1355-e1359. PubMed ID: 30171077
[TBL] [Abstract][Full Text] [Related]
9. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G
Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.
Burger MC; Mildenberger IC; Wagner M; Mittelbronn M; Steinbach JP; Bähr O
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353668
[TBL] [Abstract][Full Text] [Related]
11. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.
Quant EC; Norden AD; Drappatz J; Muzikansky A; Doherty L; Lafrankie D; Ciampa A; Kesari S; Wen PY
Neuro Oncol; 2009 Oct; 11(5):550-5. PubMed ID: 19332770
[TBL] [Abstract][Full Text] [Related]
12. Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with ("pseudo-randomized") treatment allocation by the health insurance provider.
Hofmann S; Schmidt MA; Weissmann T; Eyüpoglu I; Strnad A; Semrau S; Fietkau R; Putz F; Lettmaier S
J Neurooncol; 2020 Jun; 148(2):373-379. PubMed ID: 32409944
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in Recurrent High-Grade Gliomas: A Canadian Retrospective Study.
Lim Fat MJ; Maurice C; Maganti M; Mason WP
Can J Neurol Sci; 2018 Jan; 45(1):56-61. PubMed ID: 29151389
[TBL] [Abstract][Full Text] [Related]
14. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.
Levin VA; Chan J; Datta M; Yee JL; Jain RK
J Neurooncol; 2017 Sep; 134(2):325-330. PubMed ID: 28631191
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab is active as a single agent against recurrent malignant gliomas.
Agha CA; Ibrahim S; Hassan A; Elias DA; Fathallah-Shaykh HM
Anticancer Res; 2010 Feb; 30(2):609-11. PubMed ID: 20332478
[TBL] [Abstract][Full Text] [Related]
16. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma.
Thompson EM; Dosa E; Kraemer DF; Neuwelt EA
Neurosurgery; 2010 Jul; 67(1):87-93. PubMed ID: 20559095
[TBL] [Abstract][Full Text] [Related]
17. Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab.
Blumenthal DT; Kanner AA; Aizenstein O; Cagnano E; Greenberg A; Hershkovitz D; Ram Z; Bokstein F
World Neurosurg; 2018 Feb; 110():e727-e737. PubMed ID: 29183864
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Schaub C; Tichy J; Schäfer N; Franz K; Mack F; Mittelbronn M; Kebir S; Thiepold AL; Waha A; Filmann N; Banat M; Fimmers R; Steinbach JP; Herrlinger U; Rieger J; Glas M; Bähr O
J Neurooncol; 2016 Aug; 129(1):93-100. PubMed ID: 27193554
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases.
Miyatake S; Furuse M; Kawabata S; Maruyama T; Kumabe T; Kuroiwa T; Ono K
Neuro Oncol; 2013 Jun; 15(6):650-5. PubMed ID: 23460324
[TBL] [Abstract][Full Text] [Related]
20. Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis.
Cho SJ; Kim HS; Suh CH; Park JE
Korean J Radiol; 2020 Jul; 21(7):908-918. PubMed ID: 32524791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
